Connect with us

Press Release

Sonar Sciences Launches Platform for Testing and Publishing Algorithmic Trading Strategies

Published

2 months ago

on

The platform validates each strategy against four years of cross-venue market data and flags statistical overfitting before a result reaches a subscriber

DE, United States, 6th Aug 2026 – Sonar Sciences, a strategy-research platform for algorithmic and rules-based traders, gives pro traders a structured way to build a trading hypothesis, test it against four years of cross-venue price data, and see exactly where it holds up and where it breaks, before that strategy is ever shown to a subscriber or tied to a dollar of real capital.

The platform arrives at a moment when trading-signal marketplaces have grown faster than the tools that verify what those signals actually do. Retail platforms show equity curves. Broker forums show screenshots. Almost none of it separates a genuinely tested idea from a fitted one, and few of the tools available to independent traders were built to make that distinction visible in the first place.

Most traders can produce a backtest faster than they can tell you whether to trust it. Sonar Sciences tested the platform itself for six months before allowing a single result to be published on it, on the premise that the entire product fails the moment a number on the screen isn’t real. The validation layer exists to do the part most platforms skip: tell a pro trader when their own strategy is lying to them.

A workspace built around one question: does this actually hold up

Sonar Sciences‘ core workflow starts where most trading tools stop. A pro trader defines a strategy as an explicit, testable rule set, rather than a vague idea or a chart pattern, and runs it against Sonar Sciences‘ cross-venue data spanning four years across multiple asset classes and market regimes. The platform then returns model-level results, including a deflated Sharpe ratio calculation designed to flag when a strategy’s apparent performance is more a function of repeated testing than real edge, alongside walk-forward analysis, drawdown behavior, and out-of-sample checks that most independent traders have no repeatable way to run today.

That distinction matters more than it sounds. A strategy that looks strong on a single historical window can fall apart the moment market conditions shift, and the traders most exposed to that risk are usually the ones with the least tooling to catch it before it costs them. Sonar Sciences‘ validation layer exists specifically to surface that failure mode before a strategy reaches a live audience, not after.

Once a strategy clears validation, Sonar Sciences‘ Trader Lab gives the pro trader a full research environment to keep iterating: professional-grade charting, multi-timeframe analysis, an extensive indicator library, and bar-by-bar backtest replay with trades visualized directly on the chart. Every feature in the Lab is free today. Sonar Sciences‘ view is that a research tool should never be the thing standing between a trader and a properly tested idea, so the cost sits on the platform’s side of the ledger, not the trader’s.

What happens after a strategy is validated

A validated strategy can be published to Sonar Sciences‘ marketplace as a versioned, standardized recommendation stream, the kind of structured, machine-readable output that a broker or exchange connection can consume directly rather than a trader manually re-entering trades from a signal feed. Subscribers who follow a published strategy get a system-computed stats page rather than a self-reported screenshot, and every material event on the platform, publish, subscribe, execution, payout, is logged with a correlation ID for audit.

Money on the platform moves through an integer-exact, double-entry ledger, the same accounting discipline used in payment infrastructure, specifically because floating-point rounding has no place anywhere near a trader’s capital. Pro traders who publish a winning strategy earn a share of subscriber activity on that strategy, settled against that ledger, with identity verification required only at the point of payout rather than at every step of research and testing. Execution itself runs through Sonar Sciences‘ own pluggable connector layer, architected to support MT5 and exchange venues without rebuilding a strategy each time a new venue is added.

Sonar Sciences is explicit about where the platform stands today: live execution is being rolled out carefully, connector by connector, and the company is not marketing any capability as live before it has been verified as such. That sequencing, validate first, publish second, execute only once verified, is the same order the platform asks every pro trader to follow with their own strategies.

Three moves, one workflow

Sonar Sciences‘ team describes the platform as three moves rather than a feature list: prove it, publish it, get paid on it, in that order and never out of sequence.

The first move is proof. A pro trader writes down the rule, not just the intuition behind it, and Sonar Sciences runs that rule against the same four years of cross-venue history every other strategy on the platform is measured against, so results are comparable rather than cherry-picked. The deflated Sharpe ratio calculation exists because a high raw Sharpe ratio can simply mean a trader tested enough variations of a strategy until one of them got lucky. Deflating for that effect is standard practice in serious quantitative research and rare in retail-facing tools, and Sonar Sciences treats it as a gate rather than an optional metric.

The second move is publication, and only strategies that clear validation are eligible. A published strategy becomes a versioned recommendation stream, timestamped and immutable once live, so a subscriber following version 3 of a strategy knows exactly what changed if the pro trader later ships version 4.

The third move is payment, and it only activates once a strategy is both live and winning. Sonar Sciences takes a share of that activity rather than a flat subscription fee from the trader who built the strategy, which the company says is a deliberate choice to keep the incentive aligned with real performance rather than with volume of strategies published.

Why now

Interest in algorithmic and copy-style trading has grown steadily as retail traders look past discretionary strategies toward systems they can test and repeat, and a wider set of brokers and exchanges now expose the kind of API access that makes automated execution realistic for an individual trader rather than only a fund. That growth has outpaced the tooling available to verify whether a given system actually works, which is the gap Sonar Sciences is built to close.

Independent quant researchers and MT5 or Python-based strategy developers already have partial tools for parts of this workflow. Charting platforms are excellent for analysis but were not built to own the full path from research to publication. Broker-run signal marketplaces are built for distribution, not for disciplined testing. Full quant research environments exist but often require significant setup before a trader can see a usable result. Sonar Sciences is built for the trader in between: someone who already has a strategy or a prototype and wants a faster, more honest way to find out if it deserves to go further.

The traders Sonar Sciences is built for have usually already been burned once, either by their own overfit backtest or by someone else’s unverified claim. Sonar Sciences is not asking any pro trader to take its word that a strategy has an edge. It is built to be the place a trader goes to find out.

Availability

Sonar Sciences is free to use at sonar-sci.com. Pro traders get full use of Trader Lab and the validation engine at no cost, plus visibility on the marketplace once a strategy is published. A paid tier, Pro Desk, is planned for traders who need team, portfolio, and export capabilities beyond the core research workflow, with pricing and timing to be announced separately.

A pro trader who signs up can define a strategy and run it through the same evaluation the platform uses for every published result, with no minimum account size, no funding requirement, and no obligation to publish anything publicly. Traders can bring an existing MT5 expert advisor, a QuantConnect model, or a rule set that has only ever lived in a spreadsheet, and get the same structured evaluation.

Register directly at sonar-sci.com.

About Sonar Sciences

Sonar Sciences is a strategy-research and trade-recommendation platform for algorithmic and rules-based traders. The platform lets pro traders test trading strategies against multi-year, cross-venue market data, validate results using statistical methods designed to catch overfitting, and publish tested strategies as versioned recommendation streams for execution through Sonar Sciences‘ own broker and exchange connectors. Sonar Sciences is built on a modular architecture with an integer-exact double-entry ledger at its core, and the company has stated it will not market a capability as live until it has been independently verified. More information is available at sonar-sci.com.

Media Contact

Organization: Sonar Sciences, Friddy,Inc

Contact Person: Ava Mercer, Head of PR

Website: https://sonar-sci.com/

Email: Send Email

State: DE

Country:United States

Release id:47892

The post Sonar Sciences Launches Platform for Testing and Publishing Algorithmic Trading Strategies appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Published

4 hours ago

on

September 22, 2026

By

Ashburn, Virginia, September 22nd, 2026, FinanceWire

– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy

– Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome

– Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need

– Follows July 2026 FDA Clearance of the First-Ever IND Submitted for Peeling Skin Syndrome

– Phase 2/3 Study Expected to Initiate in 2H 2026, Enrolling up to 12 Pediatric and Adult Patients in the U.S. and Europe

– Peeling Skin Syndrome Currently Has No Approved Treatment

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003 is an investigational topical serine protease inhibitor lotion. Peeling Skin Syndrome is a rare genetic skin disease for which there is currently no approved treatment.

Key Facts

  • Fast Track Designation applies to QRX003 for the treatment of Peeling Skin Syndrome.
  • This is the first ever Fast Track Designation granted for a Peeling Skin Syndrome therapy.
  • Peeling Skin Syndrome is the second indication for which QRX003 has received Fast Track Designation. The FDA granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome on March 11, 2026.
  • The designation follows FDA clearance in July 2026 of Quoin’s Investigational New Drug (IND) application for QRX003 in Peeling Skin Syndrome. Quoin submitted that IND on June 2, 2026, and it was the first IND ever submitted to the FDA for the disease.
  • Quoin expects to initiate a Phase 2/3 clinical study of QRX003 in Peeling Skin Syndrome in the second half of 2026.
  • The IND submission was supported by clinical observations from an ongoing investigator-led pediatric study in a single subject. Significant improvements in skin appearance along with positive changes in pruritus and a number of quality-of-life measures have been recorded. Treatment is ongoing and has continued for more than 15 months, with no adverse events reported.
  • There is currently no approved treatment for Peeling Skin Syndrome.

“This is an important regulatory milestone for QRX003 and for a community that today has no approved treatment,” said Dr. Michael Myers, CEO and Co-Founder of Quoin Pharmaceuticals. “Quoin submitted the first IND ever filed with the FDA for Peeling Skin Syndrome, that IND was cleared in July, and QRX003 has now been granted Fast Track Designation for the disease. We expect to initiate our Phase 2/3 study in the second half of 2026, and we believe Fast Track status will allow us to work closely with the agency as we advance the first company-sponsored clinical study in this disease.”

Peeling Skin Syndrome Development Program

The planned Phase 2/3 study is expected to enroll up to 12 pediatric and adult patients with Peeling Skin Syndrome in the United States and Europe. In the study, QRX003 will be applied twice-daily to greater than 80% of patients’ body surface area (BSA) over a 48-week period, with an interim data review at 24 weeks. Quoin is targeting approval of QRX003 as a potential treatment for Peeling Skin Syndrome in 2028.

The IND submission was supported by clinical observations from an ongoing investigator-led pediatric study. The subject has achieved improvements across key objective severity endpoints, including the Modified Ichthyosis Area Severity Index (M-IASI), Investigator’s Global Assessment (IGA) as well as pruritus and a pediatric dermatology-specific quality-of-life measure (CDLQI). Treatment is ongoing, and after continued dosing with QRX003 for over 15 months, no adverse events have been reported.

About Fast Track Designation

The FDA’s Fast Track program is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. A therapy granted Fast Track Designation may benefit from more frequent interactions with the FDA, eligibility for rolling review of regulatory submissions, and potential qualification for Accelerated Approval and Priority Review, if relevant criteria are met.

About Peeling Skin Syndrome (PSS)

Generalized inflammatory peeling skin syndrome (PSS) is a rare autosomal recessive genodermatosis caused by loss-of-function disease-causing variants of the corneodesmosin gene (CDSN), resulting in excessive shedding of the superficial layers of the epidermis. Patients generally suffer from a variety of conditions including severe pain and chronic pruritus (itch). There is currently no approved treatment for PSS.

About QRX003

QRX003 is an investigational topical serine protease inhibitor lotion in late-stage development for Netherton Syndrome and other orphan skin diseases. QRX003 has been granted Orphan Drug, Rare Pediatric Disease, and Fast Track designations by the U.S. Food and Drug Administration, and Orphan Drug Designation in the European Union and Japan for Netherton Syndrome. QRX003 has also been granted Rare Pediatric Disease and Fast Track Designation by the FDA for Peeling Skin Syndrome. QRX003 lotion (4%) is currently being evaluated in Phase 2/3 whole-body clinical trials in patients with Netherton Syndrome. Quoin expects to initiate a Phase 2/3 clinical study of QRX003 in Peeling Skin Syndrome in the second half of 2026.

About Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others.

For more information, visit: www.quoinpharma.com or LinkedIn for updates.

Forward-Looking Statements

The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as “expect,” “intend,” “hope,” “plan,” “potential,” “anticipate,” “look forward,” “believe,” “may,” and “will,” among others. This press release contains forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: Fast Track Designation facilitating development and expediting regulatory review of therapies addressing serious conditions with significant unmet medical need; plans to initiate a Phase 2/3 clinical study of QRX003 in Peeling Skin Syndrome in the second half of 2026; Fast Track status allowing Quoin to work closely with the FDA to advance the first company-sponsored clinical study in Peeling Skin Syndrome; the study expecting to enroll up to 12 pediatric and adult patients with Peeling Skin Syndrome in the United States and Europe; QRX003 expected to be applied twice-daily to greater than 80% of a patients’ body surface area over a 48-week period, with an interim data review at 24 weeks; targeting approval of QRX003 as a potential treatment for Peeling Skin Syndrome in 2028; therapies granted Fast Track Designation benefiting from more frequent interactions with the FDA, eligibility for rolling review of regulatory submissions, and potential qualification for Accelerated Approval and Priority Review, if relevant criteria are met; and Quoin’s products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome, Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

Contacts

Jeff Ramson
jramson@pcgadvisory.com
Michael Myers
mmyers@quoinpharma.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Why Starting Work at 14 Prepared William Stapleton to Sell a Company for $300 Million

Published

4 hours ago

on

September 22, 2026

By

  • William Stapleton, President and CEO of Iron Rock Payments in Frisco, Texas, shares how early work shaped his path from private banking to entrepreneurship.

How did working from age 14 influence your career?

Texas, USA, Sep 22, 2026, ZEX PR WIRE — “I have worked since I was 14 years old to support myself and used this work ethic into college,” Stapleton says. He grew up in a working-class household in Long Beach, California. His mother is from Ecuador and his father is of German and Polish descent. Starting work young built financial responsibility and shaped his approach to business.

He played varsity baseball and water polo while working through high school. He graduated with honors from Long Beach Wilson Classical High School near the top of his class. In college, he took an unpaid internship at Salomon Brothers while balancing his studies. “I graduated college with full honors, top of my class academically,” he says. He earned a double major in Rhetorical Theory and Global Economics from California State University, Long Beach in 2006.

What did you learn in private banking that helped you as an entrepreneur?

After graduation, Morgan Stanley Private Bank recruited Stapleton to work in New York. He later joined JPMorgan Chase, where he contributed to building what is now known as the Chase Private Client program. He spent approximately seven years in private banking and advisory roles.

Working with high-net-worth clients taught him how to manage relationships, assess risk, and structure solutions. Those skills transferred directly to running a business. Understanding client needs and delivering value became the foundation of his entrepreneurial approach.

How did you transition from banking to payments?

Stapleton founded PayFacto, a credit card processing company based in Montreal. He built the company from the ground up and grew it until Visa acquired it in 2019. The sale carried an estimated valuation of $300 million.

He did not wait long to start again. In 2012, he founded Iron Rock Payments, a credit card processing company based in Frisco, Texas. The company has been recognized as an Inc. 5000 company and employs 15 people. Stapleton serves as President and CEO.

What do businesses get wrong about payment processing?

Many businesses treat payment processing as a commodity. They focus only on rates and miss the bigger picture. The right processor can improve cash flow, reduce chargebacks, and provide data that drives decisions.

Stapleton emphasizes that service matters as much as price. Businesses need a partner who understands their industry and responds quickly when issues arise. A few basis points saved on fees mean nothing if downtime costs thousands in lost sales.

What lessons from your first exit did you apply to Iron Rock Payments?

Selling PayFacto taught Stapleton the importance of building systems that scale. He learned to hire people who are better than him in specific areas and to trust them. He also realized that culture drives retention and retention drives growth.

At Iron Rock Payments, he focused on creating processes that work whether the company has 5 employees or 50. He invests in technology that automates repetitive tasks so his team can focus on client relationships. He also prioritizes transparency with clients and employees.

What advice do you give to people thinking about starting a business?

Start before you feel ready. Waiting for the perfect moment means you will never start. Stapleton began working at 14 and took an unpaid internship in college because he wanted experience more than money.

He also advises entrepreneurs to stay close to their customers. The best product ideas come from listening to what clients actually need, not from guessing. Finally, he says to protect your reputation. Trust takes years to build and seconds to destroy.

If you do nothing else

  1. Start working as early as you can to build a strong work ethic and financial discipline.

  2. Take internships or entry-level roles that teach you skills, even if the pay is low or nonexistent.

  3. Spend time in an industry before you try to disrupt it so you understand how it really works.

  4. Build systems and processes that can scale as your business grows.

  5. Hire people who are stronger than you in areas where you are weak and trust them to do their jobs.

  6. Listen to your clients and let their needs guide your product and service decisions.

  7. Protect your reputation by delivering on promises and treating people with respect.

Share this Q&A with someone who is thinking about making the leap from employee to entrepreneur or who wants to understand how early work experience shapes long-term success.

About William Stapleton

William Stapleton is President and CEO of Iron Rock Payments, a credit card processing company based in Frisco, Texas. He founded the company in 2012 after selling his previous venture, PayFacto, to Visa in 2019 at an estimated valuation of $300 million. Before entering entrepreneurship, he worked in private banking at Morgan Stanley and JPMorgan Chase, where he contributed to creating the Chase Private Client program. He graduated with full honors from California State University, Long Beach with a double major in Rhetorical Theory and Global Economics.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

David Wayne Fish makes a personal pledge: one season, one sport, no missed games

Published

5 hours ago

on

September 22, 2026

By

California, USA, Sep 22, 2026, ZEX PR WIRE — David Wayne Fish is putting a specific commitment on the record. With six kids moving through baseball, football, and tennis across overlapping seasons, he says the easiest thing to let slip is presence. So he is naming the standard out loud.

“If one of my kids has a game or a practice, someone from this family is there,” Fish says. “That’s the whole pledge. It sounds simple because it should be simple. The hard part is building a life where you can actually keep it.”

Fish runs healthcare and wellness companies as a consultant and CEO, work that does not pause for a Tuesday scrimmage. He is not pretending otherwise. The pledge is not about having endless free time. It is about deciding in advance what wins when a calendar conflict shows up.

Why he is saying it publicly

Fish has coached football, baseball, and helped organize tennis for years. He says most parents do not fail their kids through some dramatic absence. They fail them through a hundred small ones that never get flagged as decisions at all.

“Nobody skips a game and thinks of it as a broken promise,” he says. “It just looks like a scheduling problem. I wanted to write my own rule down so it stops being negotiable case by case.”

He credits his own father, and the model of family life he grew up with in Michigan, for the instinct behind this. Fish says he was raised around the idea that a father’s job includes showing up, not just providing.

What the commitment actually covers

The pledge Fish is making has a few concrete parts:

Every game gets a family face in the stands. Not every game gets David personally, with six kids and overlapping seasons that is not realistic, but every game gets someone: him, his wife, or another family member who can stand in.

Coaching commitments get finished, not started. Fish says he does not sign up to coach a season and then quietly hand it off when work gets busy. If he takes a team, he finishes the season.

Conflicts get resolved before the week starts, not during it. Fish says he sits down weekly and maps which kid has what, so trade-offs get made on a Sunday with a clear head instead of on a Wednesday in a parking lot.

“I’d rather lose an hour on Sunday mapping the week than lose a moment at my kid’s game because I’m distracted by something I should have planned around,” he says.

What he is asking of himself, not other parents

Fish is careful to frame this as his own standard, not a lecture. He is not telling other families how to run their weeks.

“I’m not in a position to tell another parent what their life allows,” he says. “I know what mine allows, and I know where I’ve cut corners before without meaning to. This is me closing that gap for myself.”

He says the pledge will get tested immediately, since his kids’ seasons rarely line up cleanly. Two games at the same hour, in two different towns, is not a hypothetical for his family. It happens.

“When that comes up, the answer isn’t ‘we’ll figure it out.’ The answer is already written down: someone from this family goes to each one,” Fish says. “I’d rather have made that call in October than try to make it in the car in March.”

Holding himself to it

Fish says he plans to track the pledge the same plain way he tracks anything else he takes seriously: a simple log of games, and who from the family was there. No app, no public scoreboard, just a habit he intends to keep himself honest about.

“If I say I’m going to do something for my kids, I want a way to check whether I actually did it,” he says. “That’s the only accountability that’s ever mattered to me.”

To read more, visit the website here.

About David Wayne Fish

David Wayne Fish is an entrepreneur based in Laguna Niguel, California. He works as a CEO and consultant to healthcare and wellness companies. Outside that work, he coaches youth football and baseball, helps organize tennis programs, and is the father of six children active in sports.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us